NEXGEL Q1 Revenue Falls 5.6%, Loss Per Share Widens to $(0.11)
NXGL is trading near its 52-week low of $0.531 (2.1% above the low) on light trading volume (0.3× avg).
Summary
NEXGEL, INC. reported a challenging first quarter for 2026, with revenue declining 5.6% year-over-year to $2.65 million. The company's financial performance worsened, as diluted loss per share expanded to $(0.11) from $(0.09) in the prior year's quarter, and net loss attributable to stockholders increased to $(0.927) million. This negative earnings report follows recent board appointments and an amended 10-K, but represents new, material financial information. The deteriorating top-line and bottom-line results are highly significant for a small-cap company already trading near its 52-week low. Traders will closely watch for any signs of stabilization in revenue and progress towards profitability in upcoming quarters, particularly given the focus on expanding consumer channels and developing proprietary medical devices.
At the time of this announcement, NXGL was trading at $0.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2M. The 52-week trading range was $0.53 to $2.89. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.